Acasă

Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay

Educatie

University of Texas M. D. Anderson Cancer Center Jan 7 2025 The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies

din zilele anterioare

Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay https://www.news-medical.net - 07.01.2025 17:09
STIRILE OREI
IN FOCUS: ‘When I die, who’s going to look after you?’ – the pains of caring for adults with disabilities https://www.channelnewsasia.com/ - 06:00
IN FOCUS: ‘When I die, who’s going to look after you?’ – the pains of caring for adults with disabilities https://www.channelnewsasia.com - 06:00
IN FOCUS: ‘I only wish to live one second longer’ – the pains of parents of adults with disabilities https://www.channelnewsasia.com/ - 06:00
IN FOCUS: ‘I only wish to live one second longer’ – the pains of parents of adults with disabilities https://www.channelnewsasia.com - 06:00
Jerry Springer's not-so-secret sauce https://www.msnbc.com/ - 12:36
© Copyright 2017 Mediafax SA | Termeni și condiţii | About cookies | Confidentialitate

monitoruldestiri@mediafax.ro

Fotografiile folosite de monitoruldestiri.ro sunt proprietatea Mediafax. Este interzisă republicarea acestora în lipsa unui acord din partea Mediafax. Pentru a obține acest acord, vă rugăm să ne contactați.